Spero Therapeutics Inc
Company Profile
Business description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Contact
675 Massachusetts Avenue
14th Floor
CambridgeMA02139
USAT: +1 857 242-1600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
32
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,757.90 | 13.20 | -0.15% |
| CAC 40 | 7,671.36 | 12.37 | -0.16% |
| DAX 40 | 23,365.80 | 68.85 | -0.29% |
| Dow JONES (US) | 42,215.80 | 299.29 | -0.70% |
| FTSE 100 | 8,845.46 | 11.43 | 0.13% |
| HKSE | 23,710.69 | 269.61 | -1.12% |
| NASDAQ | 19,521.09 | 180.12 | -0.91% |
| Nikkei 225 | 38,885.15 | 348.41 | 0.90% |
| NZX 50 Index | 12,627.32 | 12.03 | -0.10% |
| S&P 500 | 5,982.72 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,531.20 | 10.10 | -0.12% |
| SSE Composite Index | 3,388.81 | 1.40 | 0.04% |